Cargando…

Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma

Aggressive T cell lymphomas are a subgroup of lymphomas with a particularly poor prognosis. This is especially true for patients with recurrent or refractory disease, who typically have limited response to salvage therapy and extremely poor overall survival. For this reason, there is a strong need t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casanova, M, Medina-Pérez, A, Moreno-Beltran, M, Mata-Vazquez, M, Rueda, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208406/ https://www.ncbi.nlm.nih.gov/pubmed/22076116 http://dx.doi.org/10.2147/TCRM.S22834

Ejemplares similares

Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
por: Rodd, Annabelle L., et al.
Publicado: (2012)

Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)

Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin
por: Kitazume, Koichi, et al.
Publicado: (2019)

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016)

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis
por: Hong, Jung Yong, et al.
Publicado: (2019)

Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate
por: Sekiguchi, Yasunobu, et al.
Publicado: (2020)

Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
por: Hong, Xiaonan, et al.
Publicado: (2019)

Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment
por: Merdin, Alparslan, et al.
Publicado: (2019)

Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment: Erratum
Publicado: (2020)

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity
por: Serova, M, et al.
Publicado: (2011)

Pralatrexate for refractory mycosis fungoides in two Japanese patients
por: Teraishi, Mika, et al.
Publicado: (2021)

Antiviral Efficacy of Pralatrexate against SARS-CoV-2
por: Bae, Joon-Yong, et al.
Publicado: (2021)

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
por: Oiwa, Kana, et al.
Publicado: (2021)

Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers
por: Scotto, Luigi, et al.
Publicado: (2020)

Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro
por: Peters, Godefridus J., et al.
Publicado: (2020)

Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial
por: Park, Seonyoung, et al.
Publicado: (2020)

Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells
por: Clark, Rachael A., et al.
Publicado: (2020)

Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers
por: Izbicka, E., et al.
Publicado: (2009)

Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients
por: Wang, Xiaobin, et al.
Publicado: (2019)

Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts
por: Tedeschi, Philip M., et al.
Publicado: (2014)

Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination
por: Tedeschi, Philip M., et al.
Publicado: (2015)

Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma
por: Aguiar-Bujanda, David, et al.
Publicado: (2015)

Betel quid, chewing habits and difficult intubation: A case report and critical appraisal of evidence for practice
por: Narendra, P. L., et al.
Publicado: (2015)

Subjective Appraisal and Orientations in Difficult Life Situations as Predictors of Coping Strategies
por: Bityutskaya, Ekaterina V., et al.
Publicado: (2021)

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma
por: Kinahan, Cristina, et al.
Publicado: (2020)

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia
por: Tucker, David L, et al.
Publicado: (2015)

Has the time to come leave the “watch-and-wait” strategy in newly diagnosed asymptomatic follicular lymphoma patients?
por: Rueda, Antonio, et al.
Publicado: (2012)

Adenomyosis: Difficult to Diagnose, and Difficult to Treat
por: Wood, C.
Publicado: (2001)

Difficult-to-treat asthma, is it really difficult?
por: Al-Hajjaj, Mohamed S.
Publicado: (2011)

Critical appraisal of lurasidone in the management of schizophrenia
por: Caccia, Silvio, et al.
Publicado: (2012)

Not so critical appraisal of dapagliflozin
por: Doggrell, Sheila A
Publicado: (2014)

Critical Appraisal --- The Response
por: Garg, Ritesh, et al.
Publicado: (2018)

Critical appraisal of the literature
por: FERREIRA, ÁLIDA ROSÁRIA SILVA, et al.
Publicado: (2021)

A Critical Appraisal of Insulin Treatment
por: Stowers, John M.
Publicado: (1972)

Critically Ill Pediatric Oncology Patients: A Difficult-to-treat Population
por: Poddar, Banani
Publicado: (2021)

Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal
por: Raderer, Markus, et al.
Publicado: (2023)

Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals
por: Saito, Yasushi
Publicado: (2009)

Cannabinoids in the management of difficult to treat pain
por: Russo, Ethan B
Publicado: (2008)

COVID-19: Critical appraisal of the evidence()
por: González Rodríguez, Paz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9h6b3t93p4f2ie2t0ugu60ufj3